[Experiment study of alendronate in the prevention and treatment of aseptic loosening of prosthesis].
OBJECTIVE
To investigate the effect of alendronate on the prevention and treatment of aseptic loosening of prosthesis.


METHODS
A rat model of particle-induced osteolysis was used. Thirty-xis SD rats were divided into three groups: negative control group, positive control group and experiment group. Alendronate was administered by ig in experiment group. Positive control group and experiment group received intro-articular injections of ultrahigh molecular weight polyethylene (UHMWPE) particles at 4, 6, 8, 10 weeks postoperatively. Negative control group was received injection with mixture solution of mouse serum and PBS only. All animals were sacrificed at 12 weeks after operation for histologic examination. In vitro human peripheral blood mononuclear (PBMC)were separated and cultured and divided into five groups as group A: PBMC group, group B: PBMC and particles,group C:PBMC and particles with 10(-4) mol/L alendronate, group D:PBMC and particles with 10(-5) mol/L alendronate, group E: PBMC and particles with 10(-6) mol/L alendronate. The production of IL-1beta, IL-6, TNF-alpha in each group were tested.


RESULTS
Alendronate could prevent particle-induced osteolysis. The production of IL-1beta, IL-6, TNF-alpha was inhibited when alendronate was used.


CONCLUSIONS
Alendronate can inhibit bone absorptive factors expression induced by wear particles and may be used in the prevention and treatment of aseptic loosening of prosthesis.
Chen
Ming
M
Department of Orthopaedics, Puai Hospital of Wuhan, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430033, Hubei, China. cm19720@163.com
Zheng
Qiong
Q
Fang
Zhen-Hua
ZH
Kan
Wu-Sheng
WS
D019386:Alendronate / Q000008:administration & dosage*; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D005260:Female; D006801:Humans; D007595:Joint Prosthesis / Q000009:adverse effects*; D007596:Joints / Q000378:metabolism / Q000601:surgery; D008297:Male; D010014:Osteolysis / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control*; D011475:Prosthesis Failure; D051381:Rats; D017207:Rats, Sprague-Dawley
D016207:Cytokines; D019386:Alendronate